Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dynamic MRI of Human Subarachnoid Space Using Intrathecal Gadobutrol
NCT07796360Phase 1Not yet recruiting
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Nov 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gadobutrol, sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoint: Occurrence of intervention-emergent adverse events at 12 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
gadobutrol
Beyond the preview
Go deeper on NCT07796360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07796360.